tiprankstipranks
Analyst Profile
Followed by 172 other investors
.
Joel Beatty

Joel Beatty

Robert W. Baird
Wall Street Analyst
Ranked #1,337 out of 8,047 Analysts on TipRanks (#2,332 out of 21,521 overall experts)

Success Rate

52%
135 out of 258 Profitable Transactions

Average Return

7.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Joel Beatty's ratings since 2016 and opened each position for the duration of 1 Year:
52.33% of your transactions would have been profitable with an average return of 7.1%

Stock Rating Distribution

377Ratings
71.62% Buy
24.14% Hold
4.24% Sell
Distribution of Joel Beatty's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Inovio Pharmaceuticals
(INO)
Rating Type:Buy
Dates:Sep 15, 2019 - Sep 15, 2020
Gain:426.20%
The most profitable rating made by Joel Beatty

Joel Beatty's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Raptor Pharmaceutical Corp.
Hold
Downgraded
100%
+63.40%
3
Dimension Therapeutics Inc
Hold
Upgraded
0%
-46.50%
4
Cidara Therapeutics
Buy
Initiated
$8.00
(1159.84% Upside)
0%
-64.40%
1
Astria Therapeutics
Buy
Reiterated
$15.00
(130.06% Upside)
0%
-48.03%
6
Novavax
Buy
Reiterated
$19.00
(-54.18% Downside)
50%
+31.33%
10
Kura Oncology
Buy
Reiterated
$25.00
(54.04% Upside)
20%
+5.28%
5
ImmunityBio
Sell
Downgraded
$0.80
(-82.30% Downside)
50%
-112.33%
6
Solid Biosciences
Sell
Downgraded
$6.00
(649.91% Upside)
100%
+74.97%
5
aTyr Pharma
Hold
Reiterated
$3.75
(5.93% Upside)
100%
+54.80%
6
Inovio Pharmaceuticals
Buy
Reiterated
$4.00
(52.09% Upside)
50%
+207.45%
2
List of latest recommendations made by Joel Beatty. Click to expand and see Joel Beatty's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More